FORM 5  
QUARTERLY LISTING STATEMENT

Name of CNSX Issuer: **Abattis Bioceuticals Corp.** (the “Issuer”).

Trading Symbol: **ATT**

This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited interim financial statements are to be filed under the *Securities* Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the CNSX.ca website.

# General Instructions

(a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.

(b) The term “Issuer” includes the CNSX Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

**SCHEDULE A: FINANCIAL STATEMENTS**

Please See Unaudited Interim Financial Statement attachment

**SCHEDULE B: SUPPLEMENTARY INFORMATION**

The supplementary information set out below must be provided when not included in Schedule A.

**1. Related party transactions**

Please see Note 10 contained in the Unaudited Interim Financial Statements attached hereto as

Schedule "A".

**2. Summary of securities issued and options granted during the period.**

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

**(a) Summary of securities issued during the period**

Please see Note 7 contained in the Unaudited Interim Financial Statements attached hereto as

Schedule "A".

**(b) Summary of Options granted during the period**

No options were granted during the period.

**3. Summary of securities as at the end of the reporting period.**

Provide the following information in tabular format as at the end of the reporting period:

# Authorized Capital stock:

Unlimited common shares, no par value

**Shares**

Issued and outstanding - common shares

Balance, March 31, 2014 57,831,082

# Incentive Stock Options:

During the period ended March 31, 2014, there were 5,643,100 options outstanding, exercisable at a weighted average exercise price of $1.05

**4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.**

|  |  |
| --- | --- |
| **Name of Director/Officer** | **Position with Issuer** |
| Michael Withrow | President, CEO & Director |
| Rene David | CFO & COO |
| Douglas Sorocco | Director |
| Terence Fealey | Director |
| Robert Hedley | Director |

**SCHEDULE C: MANAGEMENT, DISCUSSION AND ANALYSIS**

Please See Management, Discussion and Analysis attachment

# Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated June 7, 2014.

**Rene David**

Name of Director/Senior Officer

"Rene David"­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature

Chief Financial Officer

Official Capacity

|  |  |  |  |
| --- | --- | --- | --- |
| ***Issuer Details***  Name of Issuer  **Abattis Bioceuticals Corp.** | For Quarter Ended  **March 31, 2014** | | Date of Report  **2014/06/07** |
| Issuer Address  **Suite 1000, 355 Burrard Street** | | | |
| City/Province/Postal Code  **Vancouver, BC V6C 2G8** | Issuer Fax No.  **n/a** | Issuer Telephone No.  **778-896-6536** | |
| Contact Name  **Michael Withrow** | Contact Position  **President & CEO** | Contact Telephone No.  **778-896-6536** | |
| **mike.withrow@abattis.com** | **www.abattis.com** | | |